Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (Hallmark QUAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01573351
Recruitment Status : Completed
First Posted : April 9, 2012
Last Update Posted : October 9, 2015
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ) at post-treatment Week 12.

Condition or disease Intervention/treatment Phase
Hepatitis C Virus Drug: Asunaprevir Drug: Daclatasvir Drug: Peg-interferon Alfa-2a Drug: Ribavirin Phase 3

Detailed Description:
  • ASV = Asunaprevir (BMS-650032)
  • DCV = Daclatasvir (BMS-790052)
  • Peg = Peg-interferon Alfa-2a (PegIFN)
  • Rib = Ribavirin (RBV)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 398 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection
Study Start Date : May 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin

Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks

Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks

Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks

Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks

Drug: Asunaprevir
Other Name: BMS-650032
Drug: Daclatasvir
Other Name: BMS-790052
Drug: Peg-interferon Alfa-2a
Other Name: Pegasys®
Drug: Ribavirin
Other Name: Copegus®

Primary Outcome Measures :
  1. Proportion of genotype 1 subjects with SVR12, defined as HCV RNA < LOQ at post-treatment Week 12, for all subjects infected with HCV genotype 1 [ Time Frame: At 12 weeks post-treatment ]

Secondary Outcome Measures :
  1. On-treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) through the end of treatment [ Time Frame: Through the end of treatment (maximum up to 24 weeks) plus 7 days ]
  2. Proportion of subjects with SVR12 (HCV RNA < LOQ at post-treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28 gene [ Time Frame: At post-treatment Week 12 ]
  3. Proportion of subjects with HCV RNA undetectable [ Time Frame: Weeks 1, 2, 4, 6, 8 and 12; at both Weeks 4 and 12 [Extended rapid virologic response (eRVR)], end of treatment (up to 24 weeks), post-treatment Week 12 or post-treatment Week 24 ]
  4. Proportion of subjects with HCV RNA < LOQ [ Time Frame: Weeks 1, 2, 4, 6, 8 and 12; at both Weeks 4 and 12, end of treatment (up to 24 weeks), post-treatment Week 24 (SVR24) ]
  5. Proportion of patients with SVR12 (HCV RNA < LOQ at post-treatment Week 12) for HCV genotype 4 subjects [ Time Frame: Post-treatment Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, ≥ 18 years of age
  • HCV Genotype 1 or 4 who previously failed treatment with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin (P/R), classified as previous null and partial responders based on previous therapy
  • HCV RNA ≥ 10,000 IU/mL
  • Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg)
  • Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)

Exclusion Criteria:

  • Prior treatment of HCV with HCV direct acting antiviral (DAA)
  • Evidence of a medical condition contributing to chronic liver disease other than HCV
  • Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
  • Diagnosed or suspected hepatocellular carcinoma or other malignancies
  • Uncontrolled diabetes or hypertension
  • Total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL) unless subject has a documented history of Gilbert's disease
  • Alanine aminotransferase (ALT) ≥ 5x Upper limit of normal (ULN)
  • Albumin < 3.5 g/dL (35 g/L)
  • Alpha Fetoprotein (AFP) > 100 ng/mL (>82.6 IU/mL) or ≥ 50 and ≤ 100 ng/mL requires a liver ultrasound and subjects with findings suspicious of Hepatocellular carcinoma (HCC) are excluded
  • Absolute neutrophil count (ANC) < 1.5 x 1000,000,000 cells/L (< 1.2 x 1000,000,000 cells/L for Black/African-Americans)
  • Platelets < 90 x 1000,000,000 cells/L
  • Hemoglobin < 12 g/dL for females or < 13 g/dL for males
  • Any criteria that would exclude the subject from receiving P/R

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01573351

  Hide Study Locations
United States, Alabama
Alabama Liver & Digestive Specialists (Alds)
Montgomery, Alabama, United States, 36116
United States, California
Scripps Clinic
La Jolla, California, United States, 92037
Scpmg/ Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States, 90027
United States, Colorado
University Of Colorado Denver And Hospital
Aurora, Colorado, United States, 80045
South Denver Gastroenterology, Pc
Englewood, Colorado, United States, 80113
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
University Of Miami Schiff Center For Liver Diseases
Miami, Florida, United States, 33136
United States, Illinois
University Of Chicago Medical Center
Chicago, Illinois, United States, 60637-1432
United States, New York
North Shore University Hospital
Manhasset, New York, United States, 11030
United States, North Carolina
University Of North Carolina At Chapel Hill School Of Med
Chapel Hill, North Carolina, United States, 27599-7584
United States, Ohio
University Of Cincinnati
Cincinnati, Ohio, United States, 45267
United States, Oklahoma
Options Health Research, Llc
Tulsa, Oklahoma, United States, 74104
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
University Of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Gastro One
Germantown, Tennessee, United States, 38138
United States, Texas
Baylor College Of Medicine
Houston, Texas, United States, 77030
Texas Liver Institute
San Antonio, Texas, United States, 78215
United States, Virginia
Mcguire Dvamc
Richmond, Virginia, United States, 23249
United States, Wisconsin
Dean Clinic
Madison, Wisconsin, United States, 53715
Local Institution
Ciudad De Buenos Aires, Buenos Aires, Argentina, C1121ABE
Local Institution
Mar Del Plata, Buenos Aires, Argentina, 7600
Local Institution
Prov. Buenos Aires, Buenos Aires, Argentina, 1629
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada, V6Z 2K5
Local Institution
Victoria, British Columbia, Canada, V8V 3P9
Canada, Ontario
Local Institution
Toronto, Ontario, Canada, M6H 3M1
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H2L 4P9
Local Institution
Aalborg, Denmark, 9100
Local Institution
Hvidovre, Denmark, 2650
Local Institution
Odense, Denmark, 5000
Local Institution
Creteil, France, 94000
Local Institution
Montpellier Cedex 5, France, 34295
Local Institution
Nice Cedex 03, France, 06202
Local Institution
Paris Cedex 12, France, 75571
Local Institution
Paris Cedex 14, France, 75679
Local Institution
Pessac, France, 33604
Local Institution
Berlin, Germany, 13353
Local Institution
Duesseldorf, Germany, 40237
Local Institution
Frankfurt, Germany, 60590
Local Institution
Freiburg, Germany, 79106
Local Institution
Hamburg, Germany, 20246
Local Institution
Heidelberg, Germany, 69120
Local Institution
Tuebingen, Germany, 72076
Local Institution
Brescia, Italy, 25123
Local Institution
Cisanello (pisa), Italy, 56124
Local Institution
Milano, Italy, 20122
Local Institution
Palermo, Italy, 90127
Korea, Republic of
Local Institution
Bucheon-si, Korea, Republic of, 420-767
Local Institution
Busan, Korea, Republic of, 602-715
Local Institution
Busan, Korea, Republic of, 602-739
Local Institution
Busan, Korea, Republic of, 614-735
Local Institution
Daegu, Korea, Republic of, 700-721
Local Institution
Gyeongsangnam-do, Korea, Republic of, 626-770
Local Institution
Incheon, Korea, Republic of, 400-711
Local Institution
Incheon, Korea, Republic of, 403-720
Local Institution
Seoul, Korea, Republic of, 120-752
Local Institution
Seoul, Korea, Republic of, 135-710
Local Institution
Mexico, Distrito Federal, Mexico, 03720
Local Institution
Mexico City, Estado De Mexico, Mexico, 06700
Local Institution
Amsterdam, Netherlands, 1105 AZ
Local Institution
Rotterdam, Netherlands, 3015 CE
Russian Federation
Local Institution
Moscow, Russian Federation, 117593
Local Institution
Moscow, Russian Federation, 127015
Local Institution
Saint-Petersburg, Russian Federation, 194044
Local Institution
Stavropol, Russian Federation, 355000
Local Institution
Tyumen, Russian Federation, 625026
Local Institution
Alcorcon, Spain, 28922
Local Institution
Barcelona, Spain, 08916
Local Institution
Madrid, Spain, 28029
Local Institution
Sevilla, Spain, 41014
Local Institution
Gvteborg, Sweden, SE-41685
Local Institution
Stockholm, Sweden, 141 86
Local Institution
Bern, Switzerland, 3010
Local Institution
Lausanne, Switzerland, 1011
Local Institution
Chia-Yi, Taiwan, 600
Local Institution
Kaohsiung, Taiwan, 807
Local Institution
Taichung, Taiwan, 40705
Local Institution
Taipei, Taiwan, 11217
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb Identifier: NCT01573351     History of Changes
Other Study ID Numbers: AI447-029
2011-005422-21 ( EudraCT Number )
First Posted: April 9, 2012    Key Record Dates
Last Update Posted: October 9, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs